Arena Ready For Etrasimod Phase III Face-Off With Celgene's Ozanimod In UC
Executive Summary
With significant Phase II results in ulcerative colitis, Arena is planning a Phase III program for its selective S1P receptor modulator etrasimod – a drug that it thinks can best Celgene's S1P-targeting therapy ozanimod on safety and possibly efficacy.
You may also be interested in...
Pfizer’s Big Bet On Arena Pays Off With First Phase III Win For Etrasimod In UC
The company will present detailed data in the future, but top-line results show statistically significant improvement over placebo at 12 weeks in ulcerative colitis, an increasingly competitive market.
Pfizer Buys Arena For $6.7bn In Bid To Diversify In Inflammation & Immunology
The deal is a nod for Arena's turnaround strategy and could be the start of an active deal-making period for Pfizer, flush with cash.
BMS Sees Zeposia As Safer Oral Option In Ulcerative Colitis
Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response.